A splice variant in HSD17B13 (encoding the hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13) was associated with decreased serum aminotransferase levels as well as a reduced risk of NASH or fibrosis and also mitigated the risk of liver injury in persons who were genetically predisposed to fatty liver disease by the PNPLA3 (I148M) variant [67]. Here, PNPLA3 is linked to metabolic dysfunction-associated steatohepatitis.